Stanley Bergman Sells 10,785 Shares of Henry Schein (NASDAQ:HSIC) Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 10,785 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $81.20, for a total value of $875,742.00. Following the sale, the chief executive officer owned 309,092 shares in the company, valued at approximately $25,098,270.40. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Henry Schein Trading Up 1.1%

NASDAQ HSIC traded up $0.92 during trading hours on Friday, reaching $82.39. The company’s stock had a trading volume of 1,562,469 shares, compared to its average volume of 1,447,010. The firm has a fifty day simple moving average of $77.75 and a 200-day simple moving average of $72.04. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.79. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The stock has a market cap of $9.70 billion, a P/E ratio of 25.20, a P/E/G ratio of 2.43 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Institutional Trading of Henry Schein

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HSIC. Compound Planning Inc. bought a new position in Henry Schein in the fourth quarter worth approximately $275,000. Corient Private Wealth LLC grew its position in Henry Schein by 5.4% in the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock valued at $2,798,000 after purchasing an additional 1,906 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in Henry Schein by 7.8% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock valued at $326,000 after purchasing an additional 312 shares in the last quarter. State of Tennessee Department of Treasury raised its holdings in Henry Schein by 411.7% during the fourth quarter. State of Tennessee Department of Treasury now owns 75,773 shares of the company’s stock worth $5,719,000 after buying an additional 60,965 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Henry Schein by 202.4% during the fourth quarter. Mackenzie Financial Corp now owns 10,933 shares of the company’s stock valued at $834,000 after buying an additional 7,318 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HSIC has been the subject of several recent analyst reports. Morgan Stanley increased their price objective on shares of Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research report on Wednesday. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Wells Fargo & Company boosted their price objective on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday. Mizuho raised their target price on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.